Lilly Olumiant Alopecia Launch Plans Focus On Disease Awareness And Coverage
Immunology president Patrik Jonsson talked to Scrip about being first to market with a systemic treatment for alopecia areata and launch plans for the new Olumiant indication.
You may also be interested in...
The FDA approved baricitinib for the hair loss disorder despite safety concerns with JAK inhibitors. It carries the same warnings on risk of CV events and malignancy as the others in the class.
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
Gurnet Point Capital and Patient Square Capital will buy Radius Health for approximately $890m, including a contingent value right dependent on sales growth for osteoporosis drug Tymlos.